NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Tezepelumab CRSwNP Real World Study (CREW Study)

Not Yet RecruitingN/A

Sponsor: AstraZeneca

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Tezepelumab

The CREW Study is a non-interventional prospective, observational study in patients with CRSwNP that will evaluate patient-reported outcomes and describe the proportion of participants achieving treatment goals.)

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Participant must be 18 years of age or older, at the time of signing the informed consent
* Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1
* Participants who will be enrolled after index date need to have at least SNOT-22 prior (maximum of 4 weeks) to index date
* Documented SNOT-22 total score\>=30, collected within the 4 weeks prior to the first tezepelumab dose (index date)
* Treated per the Japanese Handbook for the Management of Chronic Rhinosinusitis with Nasal Polyps for at least 30 days prior to routine care visit 1
* Physician decision that participant is eligible for treatment with tezepelumab according to local approved CRSwNP label and Optimal Clinical Use Guidelines
* Patients must be able and willing to read and comprehend written instructions, to collect PROs and medication intake and to sign the informed consent document

Exclusion Criteria:

* Patients who participate in an interventional clinical trial in the last 4 months
* Known hypersensitivity to tezepelumab or any of its excipients
* Patients who have received any biologic therapy for asthma or CRSwNP
* Condition (acute or chronic) that, in the investigator's opinion, would limit the participant´s ability to complete questionnaires or participate in this study
* Pregnancy or lactation period or planning pregnancy during the study period